A subanalysis of the STRIDE trial presented at the American Diabetes Association’s 85th Scientific Sessions found that semaglutide significantly reduces the progression of peripheral artery disease by 54% in patients with type 2 diabetes, independent of baseline glycemic control and BMI. “These findings indicate that clinicians can now recognize semaglutide as a vascular protective medication, with benefits that extend beyond lowering weight or A1C," says cardiovascular surgeon Subodh Verma.
Full Story: HCPLive Network (6/21)